Conditions: Pain
Keywords: Dexmedetomidine Opioid Thoracic Surgery
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 333
Healthy volunteers: no

Brief summary:
The purpose of this study is to see if the drug, Dexmedetomidine (also known as Precedex), can reduce pain for patients having Thoracic Surgery and therefore reduce the amount of opioid drug needed after surgery. It is a drug that is already approved by the FDA (Food \& Drug Administration) for use as a sedative in hospitals and is currently used in the investigators Intensive Care Unit for this purpose. The investigators want to investigate if it also has pain relieving properties.

Detailed description:
The study involves the use of dexmedetomidine infusion intraoperatively during thoracic surgical procedures (not using an epidural) with discontinuation in the immediate postoperative period. A key feature in this study is to employ the drug infusion intraoperatively only.

Arms:
arm 1: continuous infusion of 0.4 mcg/kg/hr arm 2: continuous infusion of 0.4 mcg/kg/hr

Interventions: intervention 1: Dexmedetomidine intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_SAP_000.pdf: 
Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 1 of 23 
 
 
 
A Double-Masked Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing 
Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery 
 
PROTOCOL FACE PAGE FOR 
MSKCC THERAPEUTIC/DIAGNOSTIC PROTOCOL 
Principal Investigator/Department: 
Alessia Pedoto, MD 
Anesthesiology 
Co-Principal Investigator 
(s)/Department: 
Vivek Tim Malhotra, MD 
David Jones, MD 
Anesthesiology 
Surgery/Manhattan and 
Westchester 
Investigator  (s)/Department: 
David Amar, MD 
Prasad Adusumilli, MD 
Manjit Bains, MD 
Matthew Bott, MD 
Kenneth Cubert,MD 
Anna Dabo, MD 
Dawn Desiderio, MD 
Robert Downey, MD 
Amitabh Gulati, MD 
Joseph Hung, MD 
James Huang, MD 
James Isbell, MD 
Alexandra Lewis, MD 
Bernard Park, MD 
Valerie Rusch, MD 
Anne Kolker, MD 
Alexandra Lewis, MD 
Will Marx, MD 
Daniela Molena, MD 
Roger Padilla, MD 
Vinay Puttanniah, MD 
Howard Thaler, Ph.D. 
Kay See Tan, Ph.D. 
Gerald O‟Neill, Pharm.D. 
Anesthesiology 
Surgery 
Surgery 
Surgery/Manhattan and 
Commack 
Anesthesiology 
Anesthesiology 
Anesthesiology 
Surgery/Manhattan and 
Basking Ridge 
Anesthesiology 
Anesthesiology 
Surgery/Manhattan and 
Commack 
Surgery 
Anesthesiology 
Surgery/Manhattan, 
Commack and Basking 
Ridge 
Surgery Anesthesiology 
Anesthesiology 
Anesthesiology 
Surgery/Manhattan and 
Westchester 
Anesthesiology 
Anesthesiology 
Epidemiology & Biostatistics 
Epidemiology & Biostatistics 
Pharmacy 
Consenting Professional 
(s)/Department: 
Vivek Tim Malhotra, MD 
Alessia Pedoto, MD 
David Jones, MD 
Prasad Adusumilli, MD 
Manjit Bains, MD 
Matthew Bott, MD 
Robert Downey, MD 
Anesthesiology 
Anesthesiology 
Surgery/Manhattan and 
Westchester 
Surgery 
Surgery 
Surgery/Manhattan and 
Commack 
Surgery/Manhattan and 
Basking Ridge 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 2 of 23 
 
 
 
James Huang, MD 
James Isbell, MD 
Daniela Molena, MD 
Valerie Rusch, MD 
Bernard Park, MD 
Denise Kessel, NP 
Megan Abate, NP 
Jennifer Aviado-Langer, NP 
Surgery/Manhattan and 
Commack 
Surgery 
Surgery/Manhattan and 
Westchester 
Surgery 
Surgery/Manhattan, 
Commack and Basking 
Ridge 
Nursing 
Nursing 
Nursing 
 
 
Please Note: A Consenting Professional must have completed the mandatory Human 
Subjects Education and Certification Program. 
 
 
Memorial Sloan-Kettering Cancer Center 
1275 York Avenue 
New York, New York 10065 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 3 of 23 
 
 
 
Table of Contents 
1.0 
PROTOCOL SUMMARY AND/OR SCHEM A .................................................................................................................................. 4 
2.0 
OBJECTIVES AND SCIENTIFIC AIMS ................................................................................... 4 
3.0 
BACKGROUND AND RATIONALE ................................................................................................. 5 
4.0 
OVERVIEW OF STUDY DESIGN/INTERVENTION .................................................................... 7 
4.1 
Design ................................................................................................................................. 7 
4.2 
Intervention ......................................................................................................................... 7 
5.0 
THERAPEUTIC/DIAGNOSTIC AGENTS ............................................................................................ 7 
6.0 
CRITERIA FOR SUBJECT ELIGIBILITY .................................................................................... 8 
6.1 
Subject Inclusion Criteria ......................................................................................................... 8 
6.2 
Subject Exclusion Criteria .................................................................................................... 8 
7.0 
RECRUITMENT PLAN ............................................................................................................ 9 
8.0 
PRETREATMENT EVALUATION ......................................................................................... 10 
9.0 
TREATMENT/INTERVENTION PLAN ................................................................................... 11 
10.0 EVALUATION DURING TREATMENT/INTERVENTION ....................................................... 11 
11.0 TOXICITIES/SIDE EFFECTS .................................................................................................... 13 
12.0 CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT ........................... 15 
13.0 CRITERIA FOR REM OVAL FROM STUDY .................................................................................. 15 
14.0 BIOSTATISTICS ............................................................................................................................. 15 
15.0 
RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES ...15 
15.1  Research Participant Registration .......................................................................................... 18 
15.2 Randomization ....................................................................................................................... 18 
16.0 DATA MANAGEMENT ISSUES .................................................................................................... 18 
16.1 Quality Assurance .................................................................................................................. 19 
16.2 Data and Safety Monitoring .................................................................................................... 19 
17.0 PROTECTION OF HUMAN SUBJECTS ............................................................................... 19 
17.1 Privacy .............................................................................................................................. 20 
17.2 Serious Adverse Event (SAE) Reporting................................................................................ 20 
18.0 INFORMED CONSENT PROCEDURES ................................................................................... 22 
19.0 REFERENCES .......................................................................................................................... 22 
20.0 
Appendices…………………………………………………………………………………………...19 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 4 of 23 
 
 
Bolus Dose:0.4 mcg/kg 
Bolus 
Randomization 
Placebo: 
Infusion: 
Active Treatment 
Dexmedetomidine 
Consent 
Placebo 
Record Data for 24 
Hours Post PACU Arrival 
 
1.0 
PROTOCOL SUMMARY AND/OR SCHEM A 
 
This study is designed to assess whether the sedative Dexmedetomidine  (PRECEDEX), 
when used intraoperatively only and stopped at the end of the operative procedure,  provides 
analgesia up to 24 hours following surgery as well as fewer opioid side effects. If beneficial, 
the use of Precedex could be a component in the 23 hour surgical protocols. 
 
 
Infusion  Rate:.0.4mcg/ 
kg/h 
 
Operation End 
Discontinue Infusion. 
Transfer to PACU 
 
 
 
 
 
 
 
 
 
2.1 
OBJECTIVES AND SCIENTIFIC AIMS 
 
2.2 Primary Objective 
 
To determine if the use of intravenous dexmedetomidine intraoperatively only and stopped at 
the end of the operative procedure, provides analgesia for up to 24 hours following surgery  
as well as fewer opioid side effects. This will be measured by total opioid administered 
postoperatively in opioid equivalents (the equivalent dose in intravenous morphine as defined 
at the end of section 10.0 below).  The primary measure will be total opioid administered in 
the first 4 hours. Data will be collected up to 24 hours after arrival in PACU or discharge (if 
sooner). 
 
2.3 Secondary Objectives 
 
To explore whether the use of intravenous dexmedetomidine infusion intraoperatively: 
 
1. Improves analgesia as measured by change in Pain Numerical Rating Scale (NRS) 
preoperatively to postoperatively at rest and with activity (such as coughing). 
2. Results in fewer cumulative episodes of nausea or antiemetic doses and/or sedation 
as measured by incidence of recorded nausea, the use of antiemetics and RASS 
sedation scores, respectively. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 5 of 23 
 
 
 
3.0 
BACKGROUND AND RATIONALE 
 
The use of an epidural catheter with local anesthetic has demonstrated benefit in lessening 
certain opioid side effects such as post-operative ileus[1] by minimizing systemic opioid use 
[2]. For short stay cases, use of an epidural catheter is not routine because the risk of 
placement may not justify the short duration of benefit. An alternative means of providing 
adequate analgesia with minimal side effects must be sought. Without an epidural or another 
regional approach, opioids via intravenous patient controlled analgesics (IV-PCA) or as 
needed (prn) opioid systemic analgesics are the most common alternatives. 
 
Selective α2-adrenoceptor agonists such as clonidine already have approved uses for both 
acute and chronic pain when given epidurally. By interrupting pain signal transmission to the 
brain, α2-adrenoceptor agonists produce analgesia at presynaptic and postjunctional alpha2- 
adrenoceptors in the spinal cord[3]. Activation of the former at the locus coeruleus results in 
decreased norepinephrine release in descending neural pathways which decreases pain 
transmission at the spinal cord. Other regions identified to have a high density of α2- 
adrenoceptors include the substantia gelatinosa, and the intermediolateral cell column , sites 
of major pain signaling[4]. 
 
Dexmedetomidine is the active dextro-isomer of medetomidine with 8 times more specificity 
for α2-adrenoceptors than clonidine. It has sympatholytic, sedative, and analgesic properties 
but without significant respiratory effects.  Unlike clonidine, it may be given intravenously to 
achieve analgesic effect.  Dexmedetomidine was approved in 1999 for short-term use of less 
than 24 hours as a sedative in mechanically ventilated patients in the intensive care unit [5]. 
Sedative effects are observed within 5 minutes following intravenous dexmedetomidine 
administration. Unlike other sedatives such as midazolam and propofol, patients on 
dexmedetomidine were sedated but easily arousable without respiratory depression[6].  Its 
sedative, sympatholytic and pro-respiratory properties allow it to be used as an adjunct to 
general anesthesia resulting in lower anesthetic doses  (17-50%) with more rapid return to a 
non-anesthetized state[7]. 
 
Used off-label, dexmedetomidine has been shown in several studies to have analgesic 
properties [5-9].   Direct spinal action on α2-adrenoceptors inhibits the release of substance  
P, which also results in analgesia[10].  Randomized studies by Arain et. al. showed a 
decrease of morphine use by 66% for major intraabdominal and orthopedic surgery  
(n=34)[8]. This study may have had incomplete blinding and involved continuation of the 
dexmedetomidine infusion in the recovery room from its initiation intra-operatively.  In studies 
by Aho and colleagues, dexmedetomidine was administered at low and high bolus doses 
(no infusion) only postoperatively  (no intraoperative use) and found to be analgesic but also 
sedative[6]. Interestingly, respiratory parameters improved in the dexmedetomidine group. 
Wahlander and colleagues used IV dexmedetomidine postoperatively following thoracic lung 
surgery as an adjunct to epidural analgesia[11]. A bolus and an infusion were started 
postoperatively only and showed opioid sparing effect, but this was also associated with 
bradycardia and hypotension. Lin and colleagues demonstrated opioid sparing for patients 
undergoing hysterectomies when dexmedetomidine was used in a PCA (patient-controlled 
analgesic device). They did note dexmedetomidine related side effects of bradycardia and 
hypotension postoperatively but also reported decreased morphine induced nausea. All 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 6 of 23 
 
 
 
these effects were most pronounced in the initial 4 hours postoper atively. In all these studies, 
dexmedetomidine administration continued postoperatively with consequent hemodynamic 
effects and sedation in the recovery room as well as analgesia[12]. 
 
Patient‟s presenting for thoracic surgery often have significant preexisting lung disease which 
narrows the therapeutic window between risk and benefit, both intraoperatively and 
postoperatively. Anesthetics are adjusted intraoperatively to promote extubation, while 
postoperative analgesia must be maximized to prevent reintubation. Patients undergoing 
major procedures such as lobectomy or pneumonectomy can achieve both goals using an 
epidural catheter to minimize anesthetic and maximize analgesia. Patients undergoing 
thorascopic procedures (VATS) for wedge resections or other simpler procedures (such as 
mediastinoscopy)  are often discharged sooner (1-2 days) making the use of an epidural 
catheter sometimes impractical. 
 
In this study, we wish to examine the effect of an intraoperative only infusion of 
dexmedetomidine on postoperative pain and opioid use for patients undergoing Thoracic 
Surgery providing residual analgesia after the infusion is terminated.  These patients 
represent a population for whom epidural may provide benefit; but, for  some surgeries, the 
risk of epidural placement may outweigh the benefit. However, given that such patients may 
have significant pre-existing lung disease, there is a desire to minimize opioid use and side 
effects. Specifically, we wish to examine if there is residual analgesia postoperatively from 
dexmedetomidine if the infusion ends in the operating room.  Residual analgesia has been 
demonstrated where dexmedetomidine was used as an alternate to Propofol sedation for 
Monitored Anesthetic Care in regional cases[7] but no such examination  has occurred for 
general anesthesia cases. The infusion in this study would be started in the operating room 
by a continuous intravenous infusion.  Before arrival to the recovery room, the infusion will be 
stopped in the operating room. The goal is to assess if the intraoperative dose of 
dexmedetomidine will provide residual analgesia in the recovery room resulting in less opioid 
use and fewer opioid side effects and improved analgesia avoiding any delays in discharge. 
 
No comparable protocol of this type has yet to be undertaken (i.e. with dexmedetomidine 
used intraoperatively only). The advantage of this study design over previous designs is the 
intraoperative use of the drug infusion only during the general anesthetic. In this way, any 
sedation resulting from the drug occurs during anesthesia where it may potentiate the 
anesthetic, blunting the sympathetic response, which may maximize the cardio-protective 
effects. Also, any potential bradycardia and hypotension from the drug will be identified and 
treated in a monitored setting with anesthesia providers continually present.  Discontinuation 
of dexmedetomidine will occur before transport to the recovery room, minimizing ongoing 
side effects such as sedation, bradycardia and hypotension while allowing assessment of 
potential ongoing analgesia. The average Length of Stay over July and August 2011 was 
3.67 days for 117 patients VATs patients. Given the institution‟s goal to reduce some 
surgeries (such as VATs) to 23-hour stays, in part by maximizing analgesia and minimizing 
side effects, this study may represent a component towards that end. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 7 of 23 
 
 
 
4.0 
OVERVIEW OF STUDY DESIGN/INTERVENTION 
 
4.1 
Design 
 
In this study, we wish to examine the analgesic effect of intraoperative dexmedetomidine use 
on postoperative pain, opioid use, and opioid related side effects for patients undergoing 
Thoracic Surgery.  The study is a double masked parallel design with patients randomized to 
either an active agent (dexmedetomidine) or a placebo. The infusion will be started in the 
operating room through a continuous infusion.  Before arrival in the recovery room, the 
infusion will be stopped in the operating room and all patients will receive a dose of ketorolac 
and IV acetaminophen, if no contraindications exist. In addition, the surgeon will infiltrate the 
wound with local anesthetic. On arrival to the recovery room, all patients will receive a 
patient-controlled analgesic (PCA) of intravenous Fentanyl (or equivalent) as a rescue dose 
only, without a basal rate. In addition all patients will be given acetaminophen as a standing 
order every 8 hours and ketorolac as needed assuming no contraindicatio ns exist. 
 
The goal is to assess if the intraoperative dose of dexmedetomidine will provide residual 
analgesia in the recovery room resulting in less opioid use, improved analgesia and fewer 
opioid side effects. Analgesic use intraoperatively will be recorded to assess any 
confounding effects of dose of intraoperative opioid received on postoperative analgesia. 
Specifically, we wish to account for any post-operative analgesic effect of excess 
intraoperative opioids as this will affect the primary endpoint. Postoperative opioid use, pain 
scores and opioid side effects (use of antiemetics and RASS sedation scores) will be 
recorded to assess differences between active and placebo groups. 
 
For details on the measures used, please see section 10.0. 
 
4.2 
Intervention 
 
The study involves the use of dexmedetomidine infusion intraoperatively during thoracic 
surgical procedures (not using an epidural) with discontinuation in the immediate 
postoperative period. A key feature in this study is to employ the drug infusion 
intraoperatively only. Therefore, sedation resulting from the drug will occur during general 
anesthesia, where it may potentiate the anesthetic. Also, any potential bradycardia and 
hypotension from the drug will be identified and treated in a fully monitored setting with 
anesthesia providers continually present. 
 
For this study, the research pharmacy will prepare both the active and placebo agent in a 
syringe at a fixed concentration. This will be used on a syringe infusion pump and dosed on a 
per kg basis. The study dose of dexmedetomidine is a continuous infusion of 0.4 mcg/kg/hr. 
This  is consistent with prescribing recommendations for ICU sedation and most studies 
investigating dexmedetomidine‟s use as an analgesic[12]. . Both active and placebo agents 
will be dosed in mls in an identical fashion. Before arrival in the recovery room, the infusion 
will be stopped in the operating room. 
 
5.0 
THERAPEUTIC/DIAGNOSTIC AGENTS 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 8 of 23 
 
 
 
The active agent used in the study is dexmedetomidine, which is currently part of the MSK 
formulary. Dexmedetomidine is the active dextro-isomer of medetomidine and is about 8 
times more specific for α2-adrenoceptors than clonidine[10]. Dexmedetomidine was approved 
in 1999 for short-term use of less than 24 hours. The agent is FDA approved for use for 
sedation of non-intubated patients before and during surgical and other procedures and for 
sedation of intubated and mechanically ventilated patients during treatment in an intensive 
care unit[10].  It has no current analgesic properties, an endpoint of this study. 
 
Dexmedetomidine is rapidly distributed to tissues with a rapid distribution phase half-life of 
approximately 6 minutes and a large volume of distribution[13]. 
 
Dexmedetomidine exhibits linear kinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when 
administered by IV infusion for up to 24 hours. 
 
In subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), 
clearance values were lower than in healthy subjects. The mean clearance values for 
subjects with mild, moderate, and severe hepatic impairment were 74%, 64%, and 53% of 
those observed in the normal healthy subjects, respectively. Mean clearances for free drug 
were 59%, 51%, and 32% of those observed in the normal healthy subjects, respectively. 
Although dexmedetomidine is dosed to effect, dosage reduction may be necessary in 
patients with hepatic impairment. Because of this, evidence of liver disease represents an 
exclusion criteria. 
 
Pharmacokinetic values of dexmedetomidine were similar for patients with a creatinine 
clearance (CrCl) < 30 ml/min as compared with healthy subjects, but the pharmacokinetic 
values of the metabolites of dexmedetomidine have not been evaluated in patients with 
impaired renal function. As dexmedetomidine is extensively metabolized and most of the 
metabolites are excreted in the urine, metabolites may accumulate upon long-term infusions 
in patients with impaired renal function. 
 
6.0 
CRITERIA FOR SUBJECT ELIGIBILITY 
 
6.1 
Subject Inclusion Criteria 
 
• 
Adult patients (>=21 years old) scheduled for Thoracic Surgery. 
 
6.2 
Subject Exclusion Criteria 
 
• 
2nd or 3rd degree heart block as assessed by preoperative EKG 
• 
Use of dexmedetomidine within 28 days prior to day of surgery 
• 
Use of long acting opioids pre-operatively 28 days prior to day of surgery 
• 
Current or past diagnosis of a Major Psychiatric disorder precluding adequate 
outcome responses such as Schizophrenia, dementia, delirium etc. as recorded in 
the Pre-Operative Record. 
• 
Documentation of congestive heart failure and Ejection fraction < 30%  if recorded in 
the Pre-Operative Record. 
• 
Planned use of an epidural for surgery for post-operative pain relief 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 9 of 23 
 
 
 
• 
Contraindication to use of NSAID, Acetaminophen or IV opioids. 
• 
Any known hypersensitivity to dexmedetomidine 
• 
Pregnant or breastfeeding 
• 
Abnormal liver function tests as related to the MSK guidelines for use of IV 
Acetaminophen: 
 
Yes or NO?; Is ALT greater than 2 x Upper Limit of Normal (> 75 U/L)? 
 
• 
Abnormal renal function tests as related to contraindications to use of IV Ketorolac: 
 
Yes or No?; Is Serum Creatinine < 1.5 mg/dl? 
 
7.1 
RECRUITMENT PLAN 
 
This study will be available to all patients seen at Memorial Sloan-Kettering Cancer Center 
that meet the eligibility criteria. Patients scheduled for Thoracic Surgery will be identified for 
potential inclusion and recruited from the Thoracic Surgery clinics or Pre-Surgical 
Testing. Both men and women of all races and ethnic groups are eligible for this trial. 
 
A consenting professional (typically the Thoracic Surgeon or Nurse Practitioner in 
conjunction with the RSA) will discuss the details of the study with the patient in the pre- 
surgical clinic.  These details include but are not limited to the following: 
 
• 
That the study involves research of an FDA approved drug (for sedation) but for an 
unapproved indication (pain). 
• 
That participation is voluntary 
• 
An explanation of the purposes of the research are to determine if this drug has any 
analgesic effect and permitting a decrease in opioid side effects 
• 
The expected duration of participation is at most 24 hours or until discharge 
• 
That the patient will be randomized to this drug or placebo and that the randomization 
will be unknown unless knowledge is required. 
• 
Identification that only FDA approved drugs are being used and they are not 
experimental drugs awaiting approval. 
• 
A description of any reasonably foreseeable risks or discomforts to the patient 
• 
A description of any benefits to the patient or to others which may reasonably be 
expected from the research 
• 
A disclosure of appropriate alternative procedures or courses of treatment, such as 
not participating 
 
Patients who expressed an interest but did not sign consent in the pre-surgical clinic or pre- 
surgical testing will be contacted by phone on any day prior to surgery. If appropriate, a 
consent discussion will occur on the phone with appropriate documentation of that 
discussion. Signing of the informed consent and any outstanding questions will be completed 
just prior to surgery on the day of surgery. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 10 of 23 
 
 
 
Patients will be required to read, agree to, and sign an IRB-approved informed consent form 
prior to study participation. 
 
The goal is to recruit 280 evaluable patients total (140 per arm) over 12 months. Based on 
the withdrawal rate, we will need to recruit an estimated 335 patients to meet our target of 
evaluable participants. 
Limited Waiver of Authorization 
 
Potential research subjects will be identified by a member of the patient‟s treatment team, the 
protocol investigator, or research team at Memorial Sloan-Kettering Cancer Center  
(MSKCC). If the investigator is a member of the treatment team, s/he will screen their 
patient‟s medical records for suitable research study participants and discuss the study and 
their potential for enrolling in the research study. Potential subjects contacted by their   
treating physician will be referred to the investigator/research staff of the study. 
 
The principal investigator may also screen the medical records of patients with whom they do 
not have a treatment relationship for the limited purpose of identifying patients who would be 
eligible to enroll in the study and to record appropriate contact information in order to 
approach these patients regarding the possibility of enrolling in the study.  A screening log  
will be maintained by the research team for review of the progress and potential barriers for 
the study. 
 
 
During the initial conversation between the investigator/research staff and the patient, the 
patient may be asked to provide certain health information that is necessary to the  
recruitment and enrollment process. The investigator/research staff may also revie w portions 
of their medical records at MSKCC in order to further assess eligibility. They will use the 
information provided by the patient and/or medical record to confirm that the patient is   
eligible and to contact the patient regarding study enrollment. If the patient turns out to be 
ineligible for the research study, the research staff will destroy all information collected on the 
patient during the initial conversation and medical records review, except for any information 
that must be maintained for screening log purposes. 
 
In most cases, the initial contact with the prospective subject will be conducted either by the 
treatment team, investigator or the research staff working in consultation with the treatment 
team. The recruitment process outlined presents no more than minimal risk to the privacy of 
the patients who are screened and minimal PHI will be maintained as part of a screening log. 
For these reasons, we seek a (partial) limited waiver of authorization for the purposes of (1) 
reviewing medical records to identify potential research subjects and obtain information 
relevant to the enrollment process; (2) conversing with patients regarding possible 
enrollment; (3) handling of PHI contained within those records and provided by the potential 
subjects; and (4) maintaining information in a screening log of patients approached (if 
applicable). 
 
 
8.1 
PRETREATMENT EVALUATION 
 
All patients will be evaluated by attending surgeons in the Thoracic Service.  Extent of 
disease and potential resectability will be determined using a variety of cross-sectional 
imaging and other studies that will vary depending on the underlying diagnosis. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 11 of 23 
 
 
 
Prior to operation, the following will be performed. 
 
• 
The patient will sign informed consent for the surgery 
• 
The patient will be confirmed to have a documented pre-operative history and 
physical examination in the EPIC system. Current history will include any Psychiatric 
disorder precluding adequate outcome responses (based on investigator judgment) 
as determined by the preoperative Anesthetic Evaluation in the EPIC system. Patient 
demographics will be recorded 
• 
Standard Preoperative testing, including EKG (to determine any exclusions) will be 
confirmed 
• 
Notation will be made of any tests done as part of pre-operative clearance 
documenting ejection fraction. 
• 
Serum pregnancy test for women of childbearing potential prior to therapy (to 
determine any exclusions) as per the MSK standard prior to surgery will be followed. 
• 
A preoperative Numerical Rating Scale (NRS) for pain at rest and with activity (such 
as coughing) will be completed within 4 hours prior to surgery, in the pre-surgical 
center as a baseline. 
• 
A preoperative query for nausea, vomiting and a RASS sedation score will be 
completed within 4 hours prior to surgery, in the pre-surgical center as a baseline. 
9.0 
TREATMENT/INTERVENTION PLAN 
 
Patients scheduled for Thoracic Surgery will undergo no change in their routine care or 
preoperative testing except for inclusion of the study drug or placebo. As part of the study, 
the intravenous infusion will commence with the induction of general anesthesia. The 
infusion should end during the commencement of surgical closure , always prior to arrival in 
the recovery room.  All patients will receive a dose of ketorolac and IV acetaminophen, 
unless there is a clinical consideration to avoid dosing (e.g. concern of bleeding 
postoperatively with ketorolac). In addition, the surgeon will perform intercostal blocks as 
standard practice (unless not advisable clinically). On arrival to the recovery room, all 
patients will receive a patient-controlled analgesic (PCA) of intravenous Fentanyl (or 
equivalent) as a rescue dose only, without a basal. In addition all patients will be given 
acetaminophen as a standing order every 8 hours and ketorolac as needed assuming no 
clinical contraindications exist. There is no plan to take any specimens as part of this study. 
 
10.1 
EVALUATION DURING TREATMENT/INTERVENTION 
 
The following data will be collected from the Electronic Medical Record. 
 
 
Data recorded intraoperatively: 
• 
Total Opioid Use Intraoperatively as measured from the electronic intraoperative 
record in the EPIC system. 
• 
Average hourly % of Agent/MAC of agent used intraoperatively as measured from the 
electronic intraoperative record in the EPIC system. 
• 
Change in Heart Rate (HR) and Mean Arterial pressure (MAP) measured from the 
electronic intraoperative record in the EPIC system. The HR and MAP reading just 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 12 of 23 
 
 
 
prior to drug infusion will be taken as the baseline. The absolute change in HR and 
MAP from this baseline will be noted q5 minutes and the difference summed over the 
duration of the case. The final number will be divided by the duration of the case in 
hours. 
• 
Any clinically relevant change in Heart Rhythm as reported by intraoperative 
anesthetist in the EPIC system. 
• 
Total doses in mg or mcg of pressor agents used intraoperatively during the study 
drug infusion period as noted from the electronic intraoperative record in the EPIC 
system. These include phenylephrine, ephedrine, epinephrine and atropine. 
• 
Total volume of intravenous fluids ( crystalloids and colloids) 
• 
Duration of the operation as measured from the electronic intraoperative record in the 
EPIC system. 
 
 
Data recorded in the PACU and on the floor: 
 
• 
Opioid use for the first 24 hours (or until discharge, if sooner) as recorded in the 
hospital record (AIF-Analgesic Infusion Form) at a frequency consistent with the 
PACU and hospital routine. The PACU routine is on admission, then every 15 min x 2 
hrs then every 30min x 2 hrs then every 1 hr. The hospital routine is every 8 hours. 
• 
NRS (Numerically Rating Scale) pain scores as recorded in the hospital record (AIF) 
for the first 24 hours (or until discharge, if sooner) q4hr at rest and with any activity 
(such as coughing). The PACU routine is on admission, then every 15 min x 2 hrs 
then every 30min x 2 hrs then every 1 hr. The hospital routine is every 8 hours. 
• 
Sedation scores for the first 24 hours as recorded in the hospital record  (AIF) post- 
operatively (or until discharge, if sooner) at a frequency consistent with the PACU and 
hospital routine. Sedation scores are specifically the Richmond Agitation Sedation 
Scale, an ordinal value measuring from +4(combative)  to -5 (unarousable) and is the 
hospital standard. 
• 
Heart Rate (HR), Mean Arterial Pressure (MAP), Respiratory Rate (RR) for the first 24 
hours post-operatively (or until discharge, if sooner) as recorded in the hospital record 
at a frequency consistent with the PACU and hospital routine. 
• 
Total volume of intravenous fluids ( crystalloids and colloids) 
• 
Incidences of Hypoxia (SpO2 < 90%) as recorded in the hospital record in PACU 
Additional postoperative data recorded include: 
• 
Inability to  extubate prior to PACU as measured by presence of endotracheal tube in 
PACU and recorded by PACU on intake. 
• 
Need for re-intubation in PACU as determined by medical record. 
• 
Time  to PACU discharge (and/or readiness for discharge, if different) as recorded by 
PACU 
• 
Time to first opioid rescue as measured from PCA device record (AIF) 
Side effects to be recorded: 
• 
Cumulative incidence of nausea recorded in medical record (AIF)  at a frequency 
consistent with the PACU and hospital routine from arrival to the PACU until 24 hours 
later (or until discharge, if sooner). 
• 
Cumulative use of an antiemetic as recorded in the hospital record from arrival to the 
PACU until 24 hours later (or until discharge, if sooner). 
. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 13 of 23 
 
 
 
 
 
When the patient is discharged to the regular floor, the above measures will be recorded 
according to the floor routine (typically q8hr). 
 
All opioid doses will be converted to the equivalent dose of intravenous morphine based on 
standard MSK guidelines using the MSK interactive converter 
(http://mskweb6.mskcc.org/painservice/meds/conversion_interactive.htm) 
11.1 
TOXICITIES/SIDE EFFECTS 
 
The safety of Dexmedetomidine was assessed by the manufacturer. Those adverse 
reactions are listed below: 
From the Product Insert[13]: 
 
“From the placebo-controlled, continuous infusion trials of Precedex for sedation in the 
surgical intensive care unit setting in which 387 patients received Precedex for less than 24 
hours. The most frequently observed treatment-emergent adverse events included 
hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia and 
anemia” 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 14 of 23 
 
 
 
 
 
 
Adverse Event 
Randomized 
Dexmedetomidine
(N=387) 
Placebo 
(N=379) 
Hypotension 
28% 
13% 
Hypertension 
16% 
18% 
Nausea 
11% 
9% 
Bradycardia 
7% 
3% 
Fever 
5% 
4% 
Vomiting 
4% 
6% 
Atrial Fibrillation 
4% 
3% 
Hypoxia 
4% 
4% 
Tachycardia 
3% 
5% 
Hemorrhage 
3% 
4% 
Anemia 
3% 
2% 
Dry Mouth 
3% 
1% 
Rigors 
2% 
3% 
Agitation 
2% 
3% 
Hyperpyrexia 
2% 
3% 
Pain 
2% 
2% 
Hyperglycemia 
2% 
2% 
Acidosis 
2% 
2% 
Pleural Effusion 
2% 
1% 
Oliguria 
2% 
< 1% 
Thirst 
2% 
< 1% 
 
In addition, the following events will be reported as SAEs: 
• 
New Arrhythmia in PACU (excluding sinus tachycardia and bradycardia that does not 
require treatment with a continuous infusion agent) 
• 
Reintubation 
• 
Sedation requiring use of naloxone 
• 
Hypotension requiring a continuous infusion of a Vasopressor postoperatively 
CTCAE v4.0 will be used for toxicity grading. 
 
11.1 Complications of Surgery 
 
Patients in both study arms are scheduled to undergo routine Thoracic Surgery which will not vary 
based on involvement in this protocol. The potential complication associated with these 
procedures, such as bleeding and infection are the same as those associated with these 
procedures when done as part of routine care and will not be collected or reported unless a grade 
3 or higher.. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 15 of 23 
 
 
 
 
12.1 
CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT 
 
Primary endpoints 
 
1. Opioid sparing as measured by 
a. total opioid equivalents used postoperatively as measured by the total opioid 
administered in approximately the first 4 hours and 
Secondary endpoints to be measured include: 
1. Change in analgesia as measured by change in Pain Numerical Rating Scale (NRS) 
preoperatively to postoperatively. Specifically measured is pain: 
a. at rest, 
b. with activity (such as coughing)  and 
2. Cumulative episodes of 
a. nausea, 
b. antiemetic use and/or 
c. sedation as measured by the incidence of side effects and sedation scores, 
respectively 
 
13.1 
CRITERIA FOR REM OVAL FROM STUDY 
 
Termination of the Study Drug is left to the Anesthesiologist based upon the clinical care of 
the patient. Reasons for termination may or may not include the following: 
 
• 
New Arrhythmia (excluding sinus tachycardia and bradycardia that does not require 
treatment with a continuous infusion agent) 
• 
Suspected anaphylaxis 
 
Criteria for censoring of the patient‟s data include: 
 
• 
Patient‟s decision to withdraw prior to surgery 
• 
Conversion to open thoracotomy 
• 
Placement of Epidural Catheter prior to end of data collection 
• 
Removal of IV PCA drug 
• 
Failure to initiate the infusion. 
• 
Complete Inability to adequately obtain any NRS pain scores, e.g. secondary to 
mental status changes or death 
 
The rate of removal will be reported with the study results. Patients who are removed from 
the study intraoperatively will continued to be followed and data analyzed in an intention-to- 
treat fashion. 
14.0 
BIOSTATISTICS 
 
The goal of this randomized, double-masked study is to evaluate the extent to which intra- 
operative dexmedetomidine infusion improves post-operative analgesia in patients 
undergoing Thoracic Surgery. We will measure each patient‟s analgesic consumption 
periodic pain self-assessment and side-effects for up to 24 hours. The primary outcome 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 16 of 23 
 
 
 
measure will be opioid consumption during the approximate first four hours post-anesthesia, 
when data will be collected more frequently, dosage will be electronically recorded in real 
time and the effect is expected to be most pronounced.  All opioids will be converted to 
morphine equivalents per standard conversion tables used at Memorial Sloan Kettering 
(http://mskweb6.mskcc.org/painservice/meds/conversion_interactive.htm) 
 
The simplest measure will be a comparison of total opioid administered during that initial time 
period, averaged across patients within each treatment arm: dexmedetomidine infusion vs. 
null (saline) infusion. Opioid consumption is widely accepted as a “hard measure” in pain 
management studies. Most if not all of the opioid will be delivered by patient controlled 
analgesia (PCA) during this time period. 
 
The plan is to study 140 evaluable patients per treatment arm (total 280 evaluable patients). 
With the current withdrawal rate we expect to recruit 335 patients in total.  Approximately 50 
potential eligible patients undergo this procedure per month. If we assume only 25 patients 
per month are feasible, the study will take approximately 14 monthsto complete. This sample 
size will be sufficient to have 80% chance of having a statistically significant (p<0.05) result 
between-arms comparison for the criterion outcome, total opioid use at 4 hours. This is 
based on data from a study of analgesic requirements in similar patients 14 and the 
assumptions that the 4-hour cumulative opioid consumption (morphine-equivalents) is log- 
normally distributed and that there is 32% treatment effect, with mean consumption +/- std 
dev 4.0 +/- 4.0 mg in the control group and 2.72 +/- 2.72 mg in the Dexmedetomidine-treated 
group. Similar considerations may apply to other outcomes, such as time to first post- 
anesthesia opioid dose. 
 
The primary analysis will be a simple comparison of average opioid consumption between  
the two randomized treatment arms.  Post-operative analgesic requirements may be affected 
by demographic or clinical factors such as patients‟ age, weight, gender, American Society of 
Anesthesia Risk score, length of operation, and amount of intra-operative analgesic drugs 
administered.  Randomization will be stratified by gender (male / female) and age (<45 / 45  
to 65 / >65).In addition to the primary analysis, we will perform an ancillary analysis of 
covariance to adjust for these covariates when comparing treatment arms.  Furthermore, we 
may apply data transformation to more closely satisfy implicit assumptions of the General 
Linear Model and more readily identify possible outlying observations. 
 
We will also perform more exploratory analyses to data such as the total opioid use at 8 
hours and self-reported numeric (numerical reporting score) pain scores, applying the 
repeated measures model to the time curve or trajectory data per patient as an efficien t way 
of summarizing results.  Side effects will be reported as per-patient means and standard 
deviations for each treatment group and compared using Student‟s t-test, after applying data 
transformation if appropriate.  These analyses are exploratory because they are of 
secondary interest and we do not have prior data to estimate statistical power 
 
Accrual and withdrawal/dropout rates will be reported with the study results. Patients who 
withdraw from the study after randomization but prior to surgery (and hence did not receive 
treatment) will not be included in the analyses; patients who withdraw from the study after 
surgery will be included in the study. In rare cases in which patients receive an intraoperative 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 17 of 23 
 
 
 
treatment different from the intended randomized treatment will remain in the intended arm 
for analyses. Patients with cancelled surgeries (and hence do not have the primary outcome) 
will not be included in the analyses. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 18 of 23 
 
 
 
15.1 
RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION 
PROCEDURES 
15.2 
Research Participant Registration 
 
Confirm eligibility as defined in the section entitled Criteria for Patient/Subject Eligibility. 
 
Obtain informed consent, by following procedures defined in section entitled Informed 
Consent Procedures. 
 
During the registration process registering individuals will be required to complete a protocol 
specific Eligibility Checklist. 
 
All participants must be registered through the Protocol Participant Registration (PPR) Office 
at Memorial Sloan-Kettering Cancer Center. PPR is available Monday through Friday from 
8:30am – 5:30pm at 646-735-8000. Registrations must be submitted via the PPR Electronic 
Registration System (http://ppr/).  The completed signature page of the written consent/RA or 
verbal script/RA, a completed Eligibility Checklist and other relevant documents must be 
uploaded via the PPR Electronic Registration System. 
 
 
 
15.3 
Randomization 
 
This is a double masked placebo controlled randomized trial.  After eligibility is established 
and immediately after consent is obtained, patients will be registered in the Protocol 
Participant Registration (PPR) system. Patients will be randomized using the Clinical 
Research Database (CRDB) at the time of registration, by calling the MSKCC PPR office at 
646-735-8000 between the hours of 8:30am and 5:30pm, Monday – Friday.  Randomization 
will be accomplished by the method of random permuted block, stratified by gender (male  / 
female) and age (<45 / 45 to 65 / >65).  Since this is a double masked study, the patients‟ 
treatment assignments can be viewed in the CRDB only by the hospital pharmacists who are 
dispensing the study drugs. The patient‟s randomization status will also be unblinded at the 
request of clinical personnel if medical care warrants such knowledge to adequately treat the 
patient including development of a new arrhythmia (excluding sinus tachycardia and 
bradycardia that does not require treatment), use of vasopressor infusion intraoperatively 
suspected anaphylaxis. 
 
16.1 
DATA MANAGEMENT ISSUES 
 
A Research Study Assistant (RSA) will be assigned to the protocol. They will identify 
potential patients eligible for consenting. They will also be re sponsible for collection of data 
from the EPIC system for intraoperative measures. They will also be responsible for data 
collection in the PACU and patient floor based on nursing records and the CIS system. 
Additional responsibilities of the RSA include project compliance, data entry, data reporting, 
regulatory monitoring, identification of potential withdrawals, and SAE reporting. The data 
recorded for this study will be entered into a secure database compliant with HIPAA 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 19 of 23 
 
 
 
regulations. Any paper used to record data will be scanned into the EMR. There are no 
patient questionnaires. 
16.2 
Quality Assurance 
 
Weekly registration reports will be generated to monitor patient accruals and completeness   
of registration of data. Routine data quality reports will be generated to assess missing data 
and inconsistencies. Accrual rates and extent of accuracy of evaluations and follow-up will be 
monitored periodically throughout the study period and potential problems will be brought to 
the attention of the Principal Investigator. 
16.3 
Data and Safety Monitoring 
 
The Data and Safety Monitoring (DSM) Plans at Memorial Sloan-Kettering Cancer Center 
were approved by the National Cancer Institute in September 2001. The plans address the 
new policies set forth by the NCI in the document entitled “Policy of the National Cancer 
Institute for Data and Safety Monitoring of Clinical Trials” which can be found at: 
http://cancertrials.nci.nih.gov/researchers/dsm/inde x.html. 
The DSM Plans at MSKCC were established and are monitored by the Office of Clinical 
Research. The MSKCC Data and Safety Monitoring Plans can be found on the MSKCC 
Intranet at: 
http://msk web2.msk cc.org/irb/index.htm 
 
 
There are several different mechanisms by which clinical trials are monitored for data, safety 
and quality. There are institutional processes in place for quality assurance (e.g., protocol 
monitoring, compliance and data verification audits, therapeutic response, and staff 
education on clinical research QA) and departmental procedures for quality control, plus 
there are two institutional committees that are responsible for monitoring the activities of our 
clinical trials programs. The committees: Data and Safety Monitoring Committee (DSMC) for 
Phase I and II clinical trials, and the Data and Safety Monitoring Board (DSMB) for Phase III 
clinical trials, report to the Center‟s Research Council and Institutional Review Board 
17.1 
PROTECTION OF HUMAN SUBJECTS 
 
Participation in this trial is voluntary.  All patients will be required to sign a statement of 
informed consent, which must conform to MSKCC IRB guidelines. 
 
1. 
Risks to the subject 
 
Human Subjects Involvement and Characteristics:  All patients at MSCKK who meet the 
inclusion criteria will be eligible.  280 evaluable patients will be entered on this study but 
based on the withdrawal rate, an estimated 335 patients will be needed to achieve that target 
of evaluable patients; patients will be 21 years of age or older.  Both men and women of all 
ethnic groups are eligible for this trial.  Pregnant and breast-feeding women are excluded 
from this study.  This protocol does not include children because the number of children is 
expected to be limited for the patient population expected to be accrued onto this study. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 20 of 23 
 
 
 
Also, the majority is already accessed by a nationwide pediatric cancer research network. 
This statement is based on exclusion 4b of the NIH Policy and Guidelines on the Inclusion of 
Children as Participants in Research involving Human Subjects. 
 
2. Adequacy of protection against risk 
 
Consent process:  All patients at MSKCC who meet the inclusion criteria will be eligible. 
Participation in the trial is voluntary.  Informed consent may be taken by those individuals 
described as Consenting Professionals.  All patients will be required to sign a statement of 
informed consent, which must conform to institutional IRB guidelines.  The informed consent 
procedure is described in section 18. 
 
Possible Toxicities/Adverse Effects:  There are risks associated with Precedex as described 
in section 11.0; however, patient screened for enrollment will have been deemed appropriate 
for treatment independent of this study. 
 
Cost: The cost of the study drug/placebo will be covered by the study. All other costs will be 
the responsibility of the patient since these are standard of care charges. 
 
Alternatives:  The alternative to this trial would be Thoracic Surgery with standard of care as 
described in section 3.0. 
 
Confidentiality:  Every effort will be made to maintain patient confidentiality.  Research and 
hospitals records are confidential.  Patients‟ names and any other identifying information will 
not be used in reports or publications resulting from this study.  Other authorized agencies 
and appropriate personnel (e.g.  Qualified monitors from MSKCC) may review patient 
records as required. 
 
17.2 
Privacy 
MSKCC‟s Privacy Office may allow the use and disclosure of protected health information 
pursuant to a completed and signed Research Authorization form. The use and disclosure of 
protected health information will be limited to the individuals described in the Research 
Authorization form. A Research Authorization form must be completed by the Principal 
Investigator and approved by the IRB and Privacy Board (IRB/PB). 
 
17.3 
Serious Adverse Event (SAE) Reporting 
 
An adverse event is considered serious if it results in ANY of the following outcomes: 
• 
Death 
• 
A life-threatening adverse event 
• 
An adverse event that results in inpatient hospitalization or prolongation of existing 
hospitalization 
• 
A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• 
A congenital anomaly/birth defect 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 21 of 23 
 
 
 
• 
Important Medical Events (IME) that may not result in death, be life threatening, or 
require hospitalization may be considered serious when, based upon medical judgment, 
they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
Note: Hospital admission for a planned procedure/disease treatment is not considered an 
SAE. 
 
SAE reporting is required as soon as the participant signs consent .  SAE reporting is 
required for 30-days after the participant‟s last investigational treatment or intervention. Any 
events that occur after the 30-day period and that are at least possibly related to protocol 
treatment must be reported. 
 
If an SAE requires submission to the IRB office per IRB SOP RR-408 „Reporting of Serious 
Adverse Events‟, the SAE report must be sent to the IRB within 5 calendar days of the event. 
The IRB requires a Clinical Research Database (CRDB) SAE report be submitted 
electronically to the SAE Office as follows: 
 
For IND/IDE trials: Reports that include a Grade 5 SAE should be sent to 
saegrade5@mskcc.org.  All other reports should be sent to saemskind@mskcc.org. 
 
For all other trials: Reports that include a Grade 5 SAE should be sent to  
saegrade5@mskcc.org.  All other reports should be sent to sae@mskcc.org. 
 
The report should contain the following information: 
Fields populated from CRDB: 
• 
Subject‟s initials 
• 
Medical record number 
• 
Disease/histology (if applicable) 
• 
Protocol number and title 
Data needing to be entered: 
• 
The date the adverse event occurred 
• 
The adverse event 
• 
The grade of the event 
• 
Relationship of the adverse event to the treatment (drug, device, or intervention) 
• 
If the AE was expected 
• 
The severity of the AE 
• 
The intervention 
• 
Detailed text that includes the following 
o A explanation of how the AE was handled 
o A description of the subject‟s condition 
o Indication if the subject remains on the study 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 22 of 23 
 
 
 
• 
If an amendment will need to be made to the protocol and/or consent form 
• 
If the SAE is an Unanticipated Problem 
 
The PI‟s signature and the date it was signed are required on the completed report. 
For IND/IDE protocols: 
The CRDB SAE report should be completed as per above instructions.  If appropriate, the 
report will be forwarded to the FDA by the SAE staff through the IND Office 
 
 
18.1 
INFORMED CONSENT PROCEDURES 
 
Before protocol-specified procedures are carried out, consenting professionals will explain  
full details of the protocol and study procedures as well as the risks involved to participants 
prior to their inclusion in the study. On the day of surgery, prior to going to Pre-Surgical Bed, 
patients will be approached by a Consenting professional who will fully consent the patients 
and answer any questions. Patients will have had the consent form to review at home prior to 
being fully consented on the day of surgery, in order to ensure that patients have ample time 
to review the consent including weighing the risks/benefits. Participants will also be informed 
that they are free to withdraw from the study at any time. All participants must sign an 
IRB/PB-approved consent form indicating their consent to participate. This consent form 
meets the requirements of the Code of Federal Regulations and the Institutional Review 
Board/Privacy Board of this Center. The consent form will include the following: 
 
1. The nature and objectives, potential risks and benefits of the intended study. 
2. The length of study and the likely follow-up required. 
3. Alternatives to the proposed study. (This will include available standard and 
investigational therapies. In addition, patients will be offered an option of supportive 
care for therapeutic studies.) 
4. The name of the investigator(s) responsible for the protocol. 
5. The right of the participant to accept or refuse study interventions/interactions and to 
withdraw from participation at any time. 
 
Before any protocol-specific procedures can be carried out, the consenting professional will 
fully explain the aspects of patient privacy concerning research specific information. In 
addition to signing the IRB Informed Consent, all patients must agree to the Research 
Authorization component of the informed consent form. 
 
Each participant and consenting professional will sign the consent form. The participant must 
receive a copy of the signed informed consent form. 
 
 
 
19.1 
REFERENCES 
 
 
1. Liu, S.S. and C.L. Wu, Effect of postoperative analgesia on major postoperative 
complications: a systematic update of the evidence. Anesth Analg, 2007. 104(3): p. 689- 
702. 


Memorial Sloan Kettering Cancer Center 
IRB#: 13-163 A(12) 
Approved: 01-NOV-2016 
Page 23 of 23 
 
 
 
2. De Windt, A.C., et al., An opioid-free anaesthetic using nerve blocks enhances rapid 
recovery after minor hand surgery in children. Eur J Anaesthesiol, 2010. 27(6): p. 521-5. 
3. Khan, Z.P., C.N. Ferguson, and R.M. Jones, alpha-2 and imidazoline receptor agonists. 
Their pharmacology and therapeutic role. Anaesthesia, 1999. 54(2): p. 146-65. 
4. Chetty, S.V., Dexmedetomidine for acute postoperative pain. South Afr J Anaesth Analg, 
2011. 17(1): p. 139-140. 
5. Aho, M., et al., Dexmedetomidine infusion for maintenance of anesthesia in patients 
undergoing abdominal hysterectomy. Anesth Analg, 1992. 75(6): p. 940-6. 
6. Aho, M.S., et al., Effect of intravenously administered dexmedetomidine on pain after 
laparoscopic tubal ligation. Anesth Analg, 1991. 73(2): p. 112-8. 
7. Arain, S.R. and T.J. Ebert, The efficacy, side effects, and recovery characteristics of 
dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg, 
2002. 95(2): p. 461-6, table of contents. 
8. Arain, S.R., et al., The efficacy of dexmedetomidine versus morphine for postoperative 
analgesia after major inpatient surgery. Anesth Analg, 2004. 98(1): p. 153-8, table of 
contents. 
9. Lin, T.F., et al., Effect of combining dexmedetomidine and morphine for intravenous 
patient-controlled analgesia. Br J Anaesth, 2009. 102(1): p. 117-22. 
10. Gerlach, A.T. and J.F. Dasta, Dexmedetomidine: an updated review. Ann Pharmacother, 
2007. 41(2): p. 245-52. 
11. Wahlander, S., et al., A prospective, double-blind, randomized, placebo-controlled study 
of dexmedetomidine as an adjunct to epidural analgesia after thoracic surgery. J 
Cardiothorac NRSc Anesth, 2005. 19(5): p. 630-5. 
12. Tan, J.A. and K.M. Ho, Use of dexmedetomidine as a sedative and analgesic agent in 
critically ill adult patients: a meta-analysis. Intensive Care Med, 2010. 36(6): p. 926-39. 
13. Hospira. Precedex Prescribing Information. [Web Page]  [cited 2011 4/4/2011]; Available 
from:  http://www.precedex.com/wp-content/uploads/2010/11/Precedex_PI.pdf. 
14. A. Ziser, J.M. Messick, D.R. Schroeder, M.S. Allen: Requirements For Postoperative 
Analgesics In Patients Undergoing Video-assisted Thoracic Surgery. The Internet Journal 
of Anesthesiology. 1999 Volume 3 Number 2. DOI: 10.5580/2735 - See more at: 
http://www.ispub.com/journal/the-internet-journal-of-anesthesiology/volume-3-number- 
2/requirements-for-postoperative-analgesics-in-patients-undergoing-video-assisted- 
thoracic-surgery.html#sthash.3JCef51J.m8FJ8udk.dpuf 
 
20.0 AppendicesAppendix AStudy Cover Summary Sheet